Ann: Phase I Clinical Trial Data Review Complete, page-2

Phase I Clinical Trial Data Review Complete - RECCE® 327 as an Intravenous Infusion Formulation

Highlights:

• Independent examiners confirm Phase I R327 (I.V.) study in 80 human subjects

  (eight cohorts), achieved all primary study end-points, met international regulatory

  standards in data and showed R327 to be safe & well tolerated

• Dosing was achieved commensurate with efficacy demonstrated in Gram-positive

  & Gram-negative animal infection models to date

• Phase I/II ‘fast infusion’ dosing of R327 IV is tracking to primary study end-points

  with expected data read-outs in H2 2023